Persistent and Breakthrough Cancer Pain

Sponsored by Asante Communications, LLC
This activity is supported by an independent education grant from Cephalon, Inc.
This activity is certified for credit.

Accrediting Provider
Albert Einstein College of Medicine and Montefiore Medical Center
Oncology Nursing Society

Date
Wednesday, September 7, 2011

Start Time
12:00 pm

End Time
1:30 pm

Room
Brera Ballroom
Level 4

Program Description
This activity will provide clinicians with an interactive forum to review evidence-based and best practice guidelines on the recognition, assessment, diagnosis, and management of persistent and breakthrough cancer pain. Led by an expert faculty panel, the program will include practical insights into the available evidence and allow participants to share their clinical decision-making using interactive video case studies and iPod touch technology.

Learning Objectives
At the conclusion of this educational activity, participants should be better prepared to:

• Comprehensively assess pain and associated functional impairment in patients with cancer 
• Define and diagnose breakthrough cancer pain and its subtypes across patient populations
• Explain the respective roles of long-acting, short-acting, and rapid-onset opioids in the management of cancer pain 
• Structure opioid therapy for cancer pain based on comprehensive and continual assessment of patient-specific risks associated with opioid pharmacology and the potential for inappropriate medication use 
• Tailor opioid-based therapy for breakthrough cancer pain based on temporal profile of the episodes, predictability, relationship with the baseline opioid regimen, and evaluation of potential benefits and risks of treatment

Faculty
Paul Glare, MD
Jeffrey A. Gudin, MD
Barbara A. Murphy, MD
Neal E. Slatkin, MD, DABPM
Sharon M. Weinstein MD, FAAHPM

Web site
www.cancerbtpprogram.com

Contact Name
Matt Wong

Contact Phone
646-563-7816

E-mail
mwong@asanteglobal.com